MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trial.
A novel combination of advanced radiation and immunotherapy shows promise for hepatocellular cancer patients who have few other treatment options available.
The Phase Ib DEPARTURE trial is the first to combine carbon-ion radiotherapy targeting macrovascular invasion with immunotherapy in advanced hepatocellular carcinoma, a population with very limited treatment options. This novel modality combination advances beyond conventional radiotherapy, potentially addressing a subset of HCC patients not well served by current systemic therapies.
What the study was
- Study design
- Phase Ib clinical trial
- Population
- Patients with advanced hepatocellular carcinoma with macrovascular invasion (MVI)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- JHEP Reports
Why it surfaced
First-in-class combination of carbon-ion RT + immunotherapy in MVI-positive HCC; Phase Ib human trial with safety/efficacy data; advanced HCC remains a high unmet need setting.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.